Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky
Tenax Therapeutics shares fell approximately 84% to 85% after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 missed both its primary and key secondary endpoints. Levi & Korsinsky is investigating potential securities law violations on behalf of TENX investors who suffered...